Original ResearchFull Report: Clinical—Alimentary TractEfficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis
Keywords
Abbreviations used in this paper
Cited by (0)
Conflicts of interest The authors disclose the following: William J. Sandborn reports research grants from Atlantic Healthcare Limited, Amgen, Genentech, Gilead Sciences, AbbVie, Janssen, Takeda, Lilly, Celgene/Receptos; consulting fees from AbbVie, Allergan, Amgen, Arena Pharmaceuticals, Avexegen Therapeutics, BeiGene, Boehringer Ingelheim, Celgene, Celltrion, Conatus, Cosmo, Escalier Biosciences, Ferring, Forbion, Genentech, Gilead Sciences, Gossamer Bio, Incyte, Janssen, Kyowa Kirin Pharmaceutical Research, Landos Biopharma, Lilly, Oppilan Pharma, Otsuka, Pfizer, Precision IBD, Progenity, Prometheus Laboratories, Reistone, Ritter Pharmaceuticals, Robarts Clinical Trials (owned by Health Academic Research Trust, HART), Series Therapeutics, Shire, Sienna Biopharmaceuticals, Sigmoid Biotechnologies, Sterna Biologicals, Sublimity Therapeutics, Takeda, Theravance Biopharma, TiGenix, Tillotts Pharma, UCB Pharma, Ventyx Biosciences, Vimalan Biosciences, Vivelix Pharmaceuticals; and stock or stock options from BeiGene, Escalier Biosciences, Gossamer Bio, Oppilan Pharma, Precision IBD, Progenity, Ritter Pharmaceuticals, Ventyx Biosciences, Vimalan Biosciences; in addition, his spouse has been a consultant for and holds stock options in Ophthotech and Progenity and has been an employee of and holds stock options in Oppilan Pharma, Escalier Biosciences, Precision IBD, Ventyx Biosciences, and Vimalan Biosciences. Marc Ferrante has received research grants from Janssen and Takeda; has done consulting for AbbVie, Boehringer Ingelheim, Ferring, Janssen, Mitsubishi Tanabe, Merck Sharp Dome, and Pfizer; and has received speaker fees from AbbVie, Boehringer Ingelheim, Chiesi, Ferring, Janssen, Lamepro, Mitsubishi Tanabe, MSD, Pfizer, Tramedico, Tillotts, and Zeria. Bal R. Bhandari reports personal fees from Delta Research Partners. Elina Berliba reports payment for research from Eli Lilly and Company. Brian G. Feagan reports grants and/or personal fees from AbbVie, ActoGeniX, Akros, Albireo Pharma, Allergan, Amgen, AstraZeneca, Avaxia Biologics Inc, Avir Pharma, Atlantic Pharma, Baxter Healthcare Corporation, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb (BMS), Calypso Biotech, Celgene, Elan/Biogen, enGene, Ferring, Genentech/Roche, gIcare Pharma, Gilead, Given Imaging, GlaxoSmithKline, Ironwood, Janssen Biotech/Centocor, Johnson & Johnson/Janssen, Kyowa Hakko Kirin Co Ltd, Lilly, Lycera Biotech, Merck, Mesoblast Pharma, Millennium, Nestles, Novo Nordisk, Novartis, Pfizer, Prometheus Therapeutics & Diagnostics, Protagonist, Receptos, and Salix; grants from Sanofi, Shire, Sigmoid Pharma, Synergy Pharma, Takeda, Teva Pharma, TiGenix, Tillotts, UCB, Vertex, VHsquared, Wyeth, Zealand, Zyngenia, Galapagos, Inception IBD Inc, Lexicon, Vivelix Pharma, Japan Tobacco Company, Ablynx, Progenity, Nextbiotix, Gossamer Pharma, Qu Biologics; and being the senior scientific officer for Robarts Clinical Trials Inc, Western University, London, Ontario, Canada. Toshifumi Hibi has received grants from Zeria Pharmaceutical, Otsuka Holdings Co Ltd, AbbVie Japan, EA Pharma, and Japan Immunoresearch Laboratories Company Limited. Jay L. Tuttle, Paul Klekotka, Stuart Friedrich, Michael Durante, MaryAnn Morgan-Cox, Janelle Laskowski, and Jochen Schmitz are current employees and shareholders of Eli Lilly and Company. Geert R. D’Haens has served as advisor for AbbVie, Ablynx, Allergan, Amakem, Amgen, AM Pharma, Arena Pharmaceuticals, AstraZeneca, Avaxia, Biogen, Bristol-Meyers Squibb, Boehringer Ingelheim, Celgene/Receptos, Celltrion, Cosmo, Covidien/Medtronic, Ferring, Dr Falk Pharma, Eli Lilly, enGene, Galapagos, Genentech/Roche, Gilead, Glaxo Smith Kline, Hospira/Pfizer, Immunic, Johnson & Johnson, Lycera, Medimetriks, Millennium/Takeda, Mitsubishi Pharma, Merck Sharp Dome, Mundipharma, Nextbiotics, Novo Nordisk, Otsuka, Pfizer/Hospira, PhotoPill, Prometheus Laboratories/Nestle, Progenity, Protagonist, Robarts Clinical Trials, Salix, Samsung Bioepis, Sandoz, Seres/Nestlé, Setpoint, Shire, Teva, TiGenix, Tillotts, TopiVert, Versant, and Vifor; and has received speaker fees from AbbVie, Biogen, Ferring, Johnson & Johnson, Merck Sharp Dome, Mundipharma, Norgine, Pfizer, Samsung Bioepis, Shire, Millennium/Takeda, Tillotts, and Vifor.
Funding This study was funded by Eli Lilly and Company.